S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
Warning: Biden’s Big Blackout is Coming (Ad)
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
Warning: Biden’s Big Blackout is Coming (Ad)
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
Putin's boneheaded mistake could make Americans INCREDIBLY RICH! (Ad)pixel
Daqo New Energy Charged Up For New Highs
TG Therapeutics Stock 300% Rally Has Legs Yet
S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
Warning: Biden’s Big Blackout is Coming (Ad)
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
Warning: Biden’s Big Blackout is Coming (Ad)
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
Putin's boneheaded mistake could make Americans INCREDIBLY RICH! (Ad)pixel
Daqo New Energy Charged Up For New Highs
TG Therapeutics Stock 300% Rally Has Legs Yet
S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
Warning: Biden’s Big Blackout is Coming (Ad)
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
Warning: Biden’s Big Blackout is Coming (Ad)
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
Putin's boneheaded mistake could make Americans INCREDIBLY RICH! (Ad)pixel
Daqo New Energy Charged Up For New Highs
TG Therapeutics Stock 300% Rally Has Legs Yet
S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
Warning: Biden’s Big Blackout is Coming (Ad)
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
Warning: Biden’s Big Blackout is Coming (Ad)
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
Putin's boneheaded mistake could make Americans INCREDIBLY RICH! (Ad)pixel
Daqo New Energy Charged Up For New Highs
TG Therapeutics Stock 300% Rally Has Legs Yet
NASDAQ:ABIO

ARCA biopharma - ABIO Stock Forecast, Price & News

$2.17
-0.03 (-1.36%)
(As of 02/8/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.17
$2.22
50-Day Range
$2.07
$2.55
52-Week Range
$1.76
$2.70
Volume
26,089 shs
Average Volume
32,796 shs
Market Capitalization
$31.27 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ABIO stock logo

About ARCA biopharma (NASDAQ:ABIO) Stock

ARCA biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of targeted therapies for cardiovascular diseases. The firm focuses on the cardiovascular pathophysiology, molecular genetics, and clinical development. Its product candidate, Gencaro is a pharmacologic beta-blocker and mild vasodilator, which is developed for the treatment of chronic heart failure and other indications. The company was founded by Michael R. Bristow and Christopher David Ozeroff in 1992 and is headquartered in Westminster, CO.

Receive ABIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ARCA biopharma and its competitors with MarketBeat's FREE daily newsletter.

ABIO Stock News Headlines

ARCA biopharma (NASDAQ:ABIO) Now Covered by StockNews.com
Frankie Muniz to race in ARCA Menards Series
Free Stock Analysis Report: Get Buy, Sell, or Hold Recommendation
Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation. pixel
James Flynn Joins ARCA biopharma Board of Directors
Don’t Let The Markets Break Your Heart
Every rose has its thorn, just like every market has its surprise. If you’re having issues in your trading, it could be that it's not you - it really is the market… Well, you’re in control. You can sit on the sideline when it feels right, or anticipate massive trend reversals with A.I. pixel
ABIO ARCA biopharma, Inc.
See More Headlines
Receive ABIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ARCA biopharma and its competitors with MarketBeat's FREE daily newsletter.

ABIO Company Calendar

Last Earnings
8/04/2021
Today
2/09/2023
Next Earnings (Estimated)
3/13/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ABIO
Employees
17
Year Founded
N/A

Profitability

Net Income
$-19,320,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.54 per share

Miscellaneous

Free Float
11,485,000
Market Cap
$31.27 million
Optionable
Not Optionable
Beta
1.60

Key Executives

  • Michael R. Bristow
    President, Chief Executive Officer & Director
  • Thomas A. Keuer
    Chief Operating Officer
  • C. Jeffrey Dekker
    Chief Financial Officer
  • Debra Marshall
    Chief Medical Officer
  • Christopher David OzeroffChristopher David Ozeroff
    Secretary, Senior Vice President & General Counsel













ABIO Stock - Frequently Asked Questions

How have ABIO shares performed in 2023?

ARCA biopharma's stock was trading at $2.37 on January 1st, 2023. Since then, ABIO shares have decreased by 8.4% and is now trading at $2.17.
View the best growth stocks for 2023 here
.

Are investors shorting ARCA biopharma?

ARCA biopharma saw a drop in short interest in the month of January. As of January 15th, there was short interest totaling 284,300 shares, a drop of 51.1% from the December 31st total of 581,500 shares. Based on an average daily volume of 38,200 shares, the days-to-cover ratio is currently 7.4 days. Approximately 2.0% of the company's shares are short sold.
View ARCA biopharma's Short Interest
.

When is ARCA biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 13th 2023.
View our ABIO earnings forecast
.

How were ARCA biopharma's earnings last quarter?

ARCA biopharma, Inc. (NASDAQ:ABIO) issued its quarterly earnings results on Wednesday, August, 4th. The biopharmaceutical company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($2.37) by $2.03.

What is Michael R. Bristow's approval rating as ARCA biopharma's CEO?

1 employees have rated ARCA biopharma Chief Executive Officer Michael R. Bristow on Glassdoor.com. Michael R. Bristow has an approval rating of 100% among the company's employees. This puts Michael R. Bristow in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ARCA biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ARCA biopharma investors own include Aurora Cannabis (ACBFF), MannKind (MNKD), Bausch Health Companies (BHC), Biocept (BIOC), Novavax (NVAX), AVEO Pharmaceuticals (AVEO), Gilead Sciences (GILD), iBio (IBIO), Nabriva Therapeutics (NBRV) and Synergy Pharmaceuticals (SGYP).

What is ARCA biopharma's stock symbol?

ARCA biopharma trades on the NASDAQ under the ticker symbol "ABIO."

Who are ARCA biopharma's major shareholders?

ARCA biopharma's stock is owned by a number of retail and institutional investors. Top institutional investors include Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Christopher David Ozeroff, Fund Lp Funicular and Robert E Conway.
View institutional ownership trends
.

How do I buy shares of ARCA biopharma?

Shares of ABIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ARCA biopharma's stock price today?

One share of ABIO stock can currently be purchased for approximately $2.17.

How much money does ARCA biopharma make?

ARCA biopharma (NASDAQ:ABIO) has a market capitalization of $31.27 million. The biopharmaceutical company earns $-19,320,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis.

How can I contact ARCA biopharma?

ARCA biopharma's mailing address is 11080 CIRCLEPOINT ROAD SUITE 140, WESTMINSTER CO, 80020. The official website for the company is arcabio.com. The biopharmaceutical company can be reached via phone at (720) 940-2200, via email at derek.cole@arcabio.com, or via fax at 720-208-9261.

This page (NASDAQ:ABIO) was last updated on 2/9/2023 by MarketBeat.com Staff